Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study

Supplemental materials of the article, "Association between biologic and nonbiologic systemic therapy for psoriasis and psoriatic arthritis and the risk of new-onset and recurrent major adverse cardiovascular events: A retrospective cohort study".

1. Supplementary figure 1. A) Time to MACE for TNF-α inhibitors, nonbiologic systemic, and phototherapy in population without a history of MACE.
2. Supplementary figure 1. B) Time to MACE for Non-TNF-α biologics, nonbiologic systemic, and phototherapy in population without a history of MACE.
3. Supplementary figure 2. A) Time to MACE for TNF-α inhibitors, nonbiologic systemic, and phototherapy in population with a history of MACE.
4. Supplementary figure 2. B) Time to MACE for Non-TNF-α biologics, nonbiologic systemic, and phototherapy in population with a history of MACE.
5. Supplementary figure 3. Risk of MACE with biologic versus nonbiologic systemic therapy according to history of MACE.
6. Supplementary Table I. Demographic and clinical characteristics of patients based on history of MACE.
7. Supplementary Table II. Risk of MACE with biologics (TNF-α inhibitor, non-TNF-α biologics), nonbiologic systemic therapy, and phototherapy according to MACE history in psoriasis and psoriatic arthritis.